Title (en)

USES OF MONOCLONAL ANTIBODY 8H9

Title (de)

ANWENDUNGEN DES MONOKLONALEN ANTIKÖRPERS 8H9

Title (fr)

UTILISATIONS D'ANTICORPS MONOCLONAL 8H9

Publication

EP 1399187 A4 20050921 (EN)

Application

EP 01983999 A 20011018

Priority

- US 0132565 W 20011018
- US 24134400 P 20001018
- US 33039601 P 20011017

Abstract (en)

[origin: WO0232375A2] This invention provides a composition comprising an effective amount of monoclonal antibody 8H9 or derivative thereof and a suitable carrier. This invention provides a pharmaceutical composition comprising an effective amount of monoclonal antibody 8H9 or a derivative thereof and a pharmaceutically acceptable carrier. This invention also provides an antibody other than the monoclonal antibody 8H9 comprising the complementary determining regions of monoclonal antibody 8H9 or a derivative thereof, capable of binding to the same antigen as the monoclonal antibody 8H9. This invention provides a substance capable of competitively inhibiting the binding of monoclonal antibody 8H9. This invention also provides an isolated scFv of monoclonal antibody 8H9 or a derivative thereof. This invention also provides the 8H9 antigen. This invention also provides a method of inhibiting the growth of tumor cells comprising contacting said tumor cells with an appropriate amount of monoclonal antibody 8H9 or a derivative thereof.

IPC 1-7

A61K 39/40; A61K 39/42; A61K 39/395; C12P 21/08; C07K 16/00

IPC 8 full level

A61K 47/48 (2006.01); **A61K 49/00** (2006.01); **A61P 43/00** (2006.01); **C07K 16/00** (2006.01); **C07K 16/18** (2006.01); **C07K 16/30** (2006.01); **C07K 16/42** (2006.01)

CPC (source: EP)

A61K 47/6865 (2017.07); **A61K 47/6873** (2017.07); **A61K 49/0004** (2013.01); **A61K 49/0006** (2013.01); **A61P 43/00** (2017.12); **C07K 16/00** (2013.01); **C07K 16/18** (2013.01); **C07K 16/3053** (2013.01); **C07K 16/4208** (2013.01); **C07K 16/4266** (2013.01); A01K 2217/05 (2013.01); C07K 2317/622 (2013.01); C07K 2317/732 (2013.01); C07K 2317/734 (2013.01); C07K 2319/00 (2013.01)

Citation (search report)

- [X] MODAK S I ET AL: "Disialoganglioside GD2 and antigen 8H9: Potential targets for antibody-based immunotherapy against desmoplastic small round cell tumor (DSRCT) adn rhabdomyosarcoma (RMS)", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 40, March 1999 (1999-03-01), & 90TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH; PHILADELPHIA, PENNSYLVANIA, USA; APRIL 10-14, 1999, pages 474, XP008050138, ISSN: 0197-016X
- [A] XU X ET AL: "Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein.", CANCER RESEARCH. 15 AUG 2000, vol. 60, no. 16, 15 August 2000 (2000-08-15), pages 4475 - 4484, XP002337817, ISSN: 0008-5472
- [PX] MODAK SHAKEEL ET AL: "Monoclonal antibody 8H9 targets a novel cell surface antigen expressed by a wide spectrum of human solid tumors", CANCER RESEARCH, vol. 61, no. 10, 15 May 2001 (2001-05-15), pages 4048 - 4054, XP002974623, ISSN: 0008-5472
- See references of WO 0232375A2

Citation (examination)

- WO 0210187 A1 20020207 - MAYO FOUNDATION [US], et al
- WO 0118021 A1 20010315 - HUMAN GENOME SCIENCES INC [US], et al
- XU HONG ET AL: "MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: potential implications for immune based therapy of human solid tumors", CANCER RESEARCH, AACR, US PHILADELPHIA, PA, vol. 69, no. 15, 1 August 2009 (2009-08-01), pages 6275 - 6281, XP002599025, ISSN: 1538-7445, [retrieved on 20090707], DOI: 10.1158/0008-5472.CAN-08-4517
- S I MODAK ET AL: "Novel Tumor-Associated Surface Antigen: Broad Distribution among Neuroectodermal, Mesenchymal and Epithelial Tumors, with Restricted Expression among Normal Tissues + 785", PEDIATRIC RESEARCH, vol. 43, 1 April 1998 (1998-04-01), pages 136 - 136, XP055133774, ISSN: 0031-3998, DOI: 10.1203/00006450-199804001-00806

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

DOCDB simple family (publication)

WO 0232375 A2 20020425; **WO 0232375 A3 20020620**; **WO 0232375 A8 20020912**; **WO 0232375 A9 20030103**; CA 2423843 A1 20020425; EP 1399187 A2 20040324; EP 1399187 A4 20050921

DOCDB simple family (application)

US 0132565 W 20011018; CA 2423843 A 20011018; EP 01983999 A 20011018